CsA plus corticosteroids superior to either alone — ORR approximately 76%
Duration and relapse
Premature cessation of CsA leads to high relapse rates
Long-term maintenance therapy often required
56% relapse rate means repeat courses are common
Etiology determines treatment strategy
Parvovirus B19 — IVIG, not immunosuppression
Immunosuppression would worsen viral replication
Anti-EPO antibody PRCA — permanent ESA cessation plus immunosuppression
No ESA re-exposure ever — class effect, all ESA products contraindicated
LGL leukemia-associated — alemtuzumab most effective
Targets CD52-expressing LGL cells
Post-HSCT PRCA — donor lymphocyte infusion or daratumumab
Targets residual host anti-donor antibodies
Treatment sequencing
Median of 2 therapies needed before remission in refractory cases
First relapse or refractoriness — second-line immunosuppression
Allogeneic HSCT reserved for highly refractory cases
Iron chelation is a parallel therapeutic priority
Transfusional iron overload is preventable cause of end-organ damage
Early chelation when ferritin > 1000 ng/mL
Patient Discharge Instructions
copy discharge instructions
Pure Red Cell Aplasia home care instructions
Follow all hematologist appointments closely — this condition requires specialist management
Take all prescribed medications exactly as directed
Do not stop cyclosporine or prednisone without speaking to your doctor first — stopping suddenly may cause relapse
Medication precautions at home
Cyclosporine — take at the same time each day for consistent blood levels
Do not take with grapefruit juice — it raises drug levels
Common side effects: tremor, gum swelling, increased hair growth, high blood pressure
Prednisone — take with food to protect stomach
Do not suddenly stop without medical guidance
Side effects include weight gain, elevated blood sugar, mood changes, bone thinning
Report any new medications to your hematologist — drug interactions are common
Infection precautions while on immunosuppression
Avoid contact with sick individuals
Wash hands frequently
Avoid raw or undercooked foods
Fever of 38.0 C or higher while on immunosuppression requires immediate medical attention
Activity and diet
Limit strenuous activity until hemoglobin has improved and hematologist approves
Adequate folate and B12 intake to support red blood cell recovery
Avoid unnecessary iron supplements unless instructed by your doctor
Warning signs — return to emergency department immediately for
Worsening fatigue, dizziness, or fainting
Chest pain or pressure
Shortness of breath at rest or with minimal activity
Fever at or above 38.0 C (100.4 F) on immunosuppressant therapy
Rapid heart rate or palpitations
Signs of bleeding — unusual bruising, blood in urine or stool
Signs of infection — cough, chills, painful urination, skin redness or swelling
Decreased urine output or leg swelling (cyclosporine kidney toxicity)
Follow-up schedule
CBC with reticulocyte count every 1–2 weeks initially during active treatment
Hematologist follow-up within 2–4 weeks of discharge
Cyclosporine blood level and kidney function check every 2–4 weeks
Ferritin level check every 1–3 months if receiving blood transfusions
Imaging follow-up as directed for thymoma or other underlying conditions
References
Guidelines and key sources
Guideline and consensus sources
Gurnari C, Maciejewski JP. How I Manage Acquired Pure Red Cell Aplasia in Adults. Blood. 2021
Means RT. Pure Red Cell Aplasia. Blood. 2016
Sawada K, Fujishima N, Hirokawa M. Acquired Pure Red Cell Aplasia: Updated Review of Treatment. British Journal of Haematology. 2008
Balasubramanian SK et al. Rational Management Approach to Pure Red Cell Aplasia. Haematologica. 2018
Key clinical studies
Yusup M et al. Efficacy and Influencing Factors of Immunosuppressive Therapy for PRCA: Meta-Analysis. Annals of Hematology. 2025
Hirokawa M et al. Long-Term Outcome of Patients With Acquired Chronic PRCA Following Immunosuppressive Therapy. British Journal of Haematology. 2015
Hemmer M et al. Pure Red Cell Aplasia Associated With Thymic Tumors, a Nationwide Retrospective Study. American Journal of Hematology. 2025
Wu X et al. Clinical Characteristics and Outcomes of 100 Adult Patients With Pure Red Cell Aplasia. Annals of Hematology. 2022
Anti-EPO antibody PRCA references
Casadevall N et al. Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin. NEJM. 2002
Bennett CL et al. Pure Red-Cell Aplasia and Epoetin Therapy. NEJM. 2004
Casadevall N et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced PRCA. European Journal of Haematology. 2004
Devathasan J et al. A Rising Cluster of Erythropoietin-Associated PRCA and Subsequent Response to Roxadustat. Nephrology. 2026
Post-HSCT and specialized PRCA references
Desai N et al. Daratumumab in the Management of Red Cell Aplasia Following Allogeneic HSCT. European Journal of Haematology. 2025
Metafuni E et al. Pure Red Cell Aplasia Among ABO Mismatched HSCT Recipients. Frontiers in Oncology. 2024
Noguchi Y et al. Outcomes of Allogeneic HSCT for Acquired Pure Red Cell Aplasia. International Journal of Hematology. 2026
Genomic and molecular references
Yang L et al. Somatic Mutations and Mutation Burden Predict Treatment Response and Survival in Adult Acquired PRCA. American Journal of Hematology. 2026
Kawakami F et al. T Cell Clonal Expansion and STAT3 Mutations in Acquired Chronic T Cell-Mediated PRCA. International Journal of Hematology. 2022
Suttichet TB et al. HLA-B46:01 and HLA-DRB1 09:01 Are Associated With Anti-rHuEPO-Induced PRCA. Scientific Reports. 2023
Congenital PRCA references
Sieff C. Diamond-Blackfan Anemia Syndrome. GeneReviews. 2025
Clark DA et al. Studies on Pure Red Cell Aplasia XI. Results of Immunosuppressive Treatment of 37 Patients. Blood. 1984
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.